Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for Behrens Baumann dust syndrome has been reported in the published literature.
No clinical trials have been registered for Behrens Baumann dust syndrome.
200 publications have been identified in PubMed for Behrens Baumann dust syndrome. Kisho has analyzed 30 by research type. Research spans Review / Meta-Analysis (73%), Diagnostic / Biomarker (7%), and Case Report / Case Series (7%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 22 | 73% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
Genetic and Rare Diseases Info Center
Common questions about Behrens Baumann dust syndrome
Testing and diagnosis research
2 |
7% |
Patient case studies | 2 | 7% |
Laboratory research | 2 | 7% |
Clinical study results | 1 | 3% |
Disease patterns and progression | 1 | 3% |
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Current opinion in clinical nutrition and metabolic care*. [Review / Meta-Analysis]
Sahoo SS (2025). [PMID: 39475954](https://pubmed.ncbi.nlm.nih.gov/39475954/). *Blood*. [Review / Meta-Analysis]
Mutai H (2025). [PMID: 39755840](https://pubmed.ncbi.nlm.nih.gov/39755840/). *Human genetics*. [Basic Science / Preclinical]
Cornejo-Sanchez DM (2025). [PMID: 40055553](https://pubmed.ncbi.nlm.nih.gov/40055553/). *European journal of human genetics : EJHG*. [Epidemiology / Natural History]
Sakuma H (2025). [PMID: 39143740](https://pubmed.ncbi.nlm.nih.gov/39143740/). *Developmental medicine and child neurology*. [Diagnostic / Biomarker]
Dotan A (2025). [PMID: 39931017](https://pubmed.ncbi.nlm.nih.gov/39931017/). *Harefuah*. [Review / Meta-Analysis]
Pignataro G (2025). [PMID: 41010942](https://pubmed.ncbi.nlm.nih.gov/41010942/). *Medicina (Kaunas, Lithuania)*. [Review / Meta-Analysis]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Progress in retinal and eye research*. [Review / Meta-Analysis]
Pena C (2025). [PMID: 40146047](https://pubmed.ncbi.nlm.nih.gov/40146047/). *Minerva medica*. [Review / Meta-Analysis]
Shabshin G (2025). [PMID: 40261331](https://pubmed.ncbi.nlm.nih.gov/40261331/). *Orthopadie (Heidelberg, Germany)*. [Review / Meta-Analysis]
AI-curated news mentioning Behrens Baumann dust syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.